Expert Interview
Discussing Thyroid Eye Disease (TED), the outlook for VRDN-001 and VRDN-003, and the THRIVE trial from Viridian
Ticker(s): VRDNInstitution: Stanford
- Assistant professor of ophthalmology at Stanford and Director of the Oculofacial plastic, Reconstructive surgery and Orbital Oncology Eyes Institute at the Byers Eye Institute at Stanford
- Specializes in aesthetic oculofacial surgery, thyroid eye disease and orbital oncology
- Research interests include the proteomic evaluation of ocular surface and orbital inflammation, modulation of neural reflexes via neurotization and neurostimulation and evaluating targeted therapies for cutaneous and orbital malignancies
How has your prescribing pattern for Tepezza evolved in response to emerging real-world evidence, particularly regarding adverse events?
What is the difference in the management of TED patients between ophthalmologists and endocrinologists, and how does multidisciplinary collaboration impact treatment outcomes?
For chronic TED patients, under what circumstances do you still prescribe Tepezza, and how does disease activity, progression, or inflammation factor into your decision?
What is your perspective on the VRDN-001 and VRDN-003 trials, including dosing amendments and the potential for these drugs to compete with or replace Tepezza?
Considering the competitive landscape, what key factors would make you switch to a new IGF-1 inhibitor (like VRDN-001), such as safety, efficacy, or convenience?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
